Patents
Literature
Patsnap Copilot is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Patsnap Copilot

79 results about "Radioimmunoassay" patented technology

A radioimmunoassay (RIA) is an immunoassay that uses radiolabeled molecules in a stepwise formation of immune complexes. A RIA is a very sensitive in vitro assay technique used to measure concentrations of substances, usually measuring antigen concentrations (for example, hormone levels in blood) by use of antibodies.

Methods and reagents to detect and characterize norwalk and related viruses

Double-stranded cDNA was synthesized from nucleic acid extracted from Norwalk virus purified from stool specimens of volunteers. One clone was isolated from a cDNA library constructed in a pUC-13 vector after amplification of the cDNA. The specificity of this cDNA (pUCNV-953) was shown by hybridization assays. The cDNA reacted with post (but not pre-) infection stool samples from Norwalk volunteers and with highly purified Norwalk virus, but not with other common enteric viruses such as hepatitis A virus and rotavirus. Finally, the probe detected virus in the same fractions of CsCl gradients in which viral antigen was detected using a specific Norwalk virus radioimmunoassay, and particles were detected by immune electron microscopy. Single-stranded RNA probes derived from the DNA clone after subcloning into an in vitro transcription vector were also used to show that the Norwalk virus contains a ssRNA genome of about 8 kb in size. The original clone was also used to detect additional cDNAs which represent at least 7 kb of nucleic acid of the Norwalk genome. The availability of a Norwalk-specific cDNA and the first partial genome sequence information allow rapid cloning of the entire genome and of establishment of sensitive diagnostic assays. Such assays can be based on detection of Norwalk virus nucleic acid or Norwalk viral antigen using polyclonal or monoclonal antibodies to proteins expressed from the cDNA or to synthetic peptides made based on the knowledge of the genome sequence. Assays using proteins deduced from the Norwlk virus genome and produced in expression systmes can measure antibody responses. Vaccines made by recombinant DNA technology are now feasible.
Owner:BAYLOR COLLEGE OF MEDICINE

One-step chemiluminiscence quantitative detection kit for hyaluronic acid

The invention relates to a chemiluminiscence kit for detecting content of hyaluronic acid in human serum, body fluid or tissue homogenate by one-step process, and belongs to the medical field of immunoassay. By solid coating and indirect enzyme labeling technology, the problem that a hyaluronic acid kit is unavailable for one-step detection is solved substantially, operation is more convenient, detection is more accurate, and reagents are more stable. The chemiluminiscence kit for detecting content of the hyaluronic acid in human serum, body fluid or tissue homogenate by one-step process comprises a calibrator, a coated board, an enzyme combination, chemiluminiscence substrate solution A and chemiluminiscence substrate solution B. The sample amount of each of the HA (hyaluronic acid) calibrator and the enzyme combination is 50 microliters in the kit, and reaction time of the one-step process is one hour. Scientific and reasonable range of normal values is determined by strict methodological appraisal, clinical measurement results are compared with a radioimmunoassay kit statistically, and accordingly the chemiluminiscence kit has the technical advantages of high sensitivity, accurate measurement, high repeatability, regent stability and the like and is worthy of vigorous popularization and application to market.
Owner:BEIJING NORTH INST OF BIOLOGICAL TECH

Effect study method and application of melatonin in prediction of ovarian reserve and IVF-ET (in-vitro fertilization and embryo transfer) outcome

InactiveCN106168621AIncrease success rateFacilitates personalized treatment plansDiagnostic recording/measuringSensorsPhysiologyOvary
The present invention discloses a method for researching the role of melatonin in predicting the outcome of ovarian reserve and in vitro fertilization-embryo transfer (IVF-ET), including: collecting basic clinical data of 61 women, and according to their ovary response to stimulation, mainly by age , the number of retrieved eggs, and the value of anti-Müllerian hormone were divided into three groups: ovarian low response group, normal group and high response group. The follicular fluid of 61 women was collected, the melatonin concentration in the follicular fluid of 61 women was measured by melatonin radioimmunoassay, and the melatonin concentration and other clinical data were analyzed in the ovarian low response group, normal group and high response group. level; analyze the relevant data of in vitro fertilization outcome in ovarian low response group, normal group, and high response group, and verify the correlation between melatonin concentration and in vitro fertilization-embryo transfer outcome; verify the relationship between melatonin level and ovarian Relevance of reserves. The invention can predict the outcome of ovarian reserve and in vitro fertilization-embryo transfer by detecting the melatonin concentration in the follicular fluid.
Owner:RENJI HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE

Method for diagnosing cardiac troponin I (cTn I) in semi-quantitative mode by employing double-indicatrix immunochromatography

The invention discloses a detection method in the technical field of biological engineering, in particular a method for diagnosing cardiac troponin I (cTn I) in a semi-quantitative mode by employing double-indicatrix immunochromatography. Acute myocardial infarction (AMI) is a serious disease in a coronary heart disease, is a common emergency among middle-aged and elderly people, and is high in death rate. According to statistics, one third to a half of patients die before being sent to a hospital. In the next 20 years, the AMI is a primary cause for death of the patients around the world. The cTn I is a reliable index which is currently acknowledged and has the highest specificity and the longest duration for myocardial infarction diagnosis. At present, cTn I detection methods which are commonly used in clinic comprise an enzyme-linked immunosorbent assay method and a radioimmunoassay method, which are time-saving, labor-saving, difficult to popularize and high in cost. An immune colloidal gold technology is quickly developed in recent years and can be widely applied to detection of communicable diseases, early pregnancy and cancers. By employing colloidal gold immunochromatography, a quick detection method for the cTn I is established. By adoption of the method, a cTn I gray area of 1 to 5 ng / ml can be subjected to semi-quantitative detection.
Owner:正元盛邦(天津)生物科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products